The Journal of clinical endocrinology and metabolism · 2006 · Clinical trial · PMID 16352683
Explore the library
Limited human evidenceLong-acting GHRH analog
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. The published human research highlighted here concerns its long-acting DAC form, not all products marketed under similar names.
Also indexed as: CJC-1295 with DAC · DAC-GRF
A clear starting point
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. The published human research highlighted here concerns its long-acting DAC form, not all products marketed under similar names.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
GHRH / GH–IGF-1
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. The published human research highlighted here concerns its long-acting DAC form, not all products marketed under similar names.
- Targets & processes
- GHRH / GH–IGF-1
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
GH and IGF-1 responses and pharmacokinetics in controlled research.
What this does not establish
The cited trial studies the long-acting DAC form and hormone responses, not proof of improved recovery or anti-aging benefit. Modified GRF (1–29) without DAC is not interchangeable.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Potential glucose intolerance, fluid retention and endocrine effects; FDA reports increased heart rate and systemic vasodilatory reactions.
Contraindications & cautions
Not an exhaustive contraindication review. Potential glucose intolerance, fluid retention and endocrine effects; FDA reports increased heart rate and systemic vasodilatory reactions.
Medication & supplement interactions
Interaction information is incomplete. Potential glucose intolerance, fluid retention and endocrine effects; FDA reports increased heart rate and systemic vasodilatory reactions.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.